By providing the dual benefit of increasing therapeutic potency while reducing toxic side effect profiles, TDZ+ represents a promising lead compound for the future development of DRD-targeted therapies in AML and potentially a variety of cancers that also aberrantly express DRD2. The gene discussed is DRD2; the disease is cancer.